Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells
- 6 January 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Gene Therapy
- Vol. 18 (5), 509-516
- https://doi.org/10.1038/gt.2010.174
Abstract
Multiple myeloma causes approximately 10% of all hematologic malignancies. We have previously shown that human T cells expressing chimeric NKG2D receptors (chNKG2D) consisting of NKG2D fused to the CD3ζ cytoplasmic domain secrete proinflammatory cytokines and kill human myeloma cells. In this study, we show chNKG2D T cells are effective in a murine model of multiple myeloma. Mice with established 5T33MM–green fluorescent protein tumors were treated with one or two infusions of chNKG2D T cells. Compared with mice treated with T cells expressing wild type (wt)NKG2D receptors, a single dose of chNKG2D T cells increased survival, with half of the chNKG2D T-cell-treated mice surviving long term. Two infusions of chNKG2D T cells led to tumor-free survival in all mice. ChNKG2D T cells were located at sites of tumor growth, including the bone marrow and spleen after intravenous injection. There was an increase in activated host T cells and NK cells at tumor sites and in serum interferon-γ after chNKG2D T-cell injection. Surviving mice were able to resist a rechallenge with 5T33MM cells but not RMA lymphoma cells, indicating that the mice developed a protective, specific memory response. These data demonstrate that chNKG2D T cells may be an effective adoptive cellular therapy for multiple myeloma.Keywords
This publication has 58 references indexed in Scilit:
- Gr-1+CD11b+ myeloid-derived suppressor cells: Formidable partners in tumor metastasisJournal of Bone and Mineral Research, 2010
- Chimeric NKG2D Expressing T Cells Eliminate Immunosuppression and Activate Immunity within the Ovarian Tumor MicroenvironmentPublished by The American Association of Immunologists ,2009
- Chimeric NKG2D T Cells Require Both T Cell- and Host-Derived Cytokine Secretion and Perforin Expression to Increase Tumor Antigen Presentation and Systemic ImmunityThe Journal of Immunology, 2009
- Posttranslational regulation of the NKG2D ligand Mult1 in response to cell stressThe Journal of Experimental Medicine, 2009
- Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative RegimensJournal of Clinical Oncology, 2008
- Chimeric NKG2D receptor–expressing T cells as an immunotherapy for multiple myelomaExperimental Hematology, 2008
- Immune reconstitution and implications for immunotherapy following haematopoietic stem cell transplantationBest Practice & Research Clinical Haematology, 2008
- MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myelomaProceedings of the National Academy of Sciences of the United States of America, 2008
- Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?Nature Clinical Practice Oncology, 2006
- Adoptive immunotherapy for cancer: building on successNature Reviews Immunology, 2006